Adaptogen

Gynostemma

Gynostemma pentaphyllum

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

6 g daily as tea is the best direct human diabetes protocol

watchEffect Window

Trial-based metabolic effects generally emerged over weeks.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Gynostemma may modestly improve insulin sensitivity, some metabolic markers, and possibly hair-health measures in one recent trial, but the evidence remains product specific and much stronger for metabolic support than for “stress resilience” claims.

Gynostemma is often marketed as an adaptogen, but the more credible human evidence is metabolic. Small trials suggest improved insulin sensitivity in type 2 diabetes, and a branded extract has shown modest body-composition benefits in overweight adults. There is also lower-confidence lipid data plus a newer 2025 hair-health trial that is interesting but still single-study and product specific. That makes gynostemma a cautious metabolic-support supplement, not a broadly proven stress or performance herb.

Gynostemma is usually framed around AMPK activation, glucose handling, and gypenoside-mediated metabolic effects. The human evidence fits that metabolic framing better than broad stress-adaptation claims.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Possible improvement in insulin sensitivity and fasting glucose

Secondary Outcomes

  • Modest product-specific body-composition benefit
  • Low-confidence adjunctive lipid support
  • Possible hair health improvement (single RCT)

Safety

Contraindications and Interactions

Contraindications

  • Recurrent hypoglycemia risk

Side effects

  • Mild GI upset

Interactions

  • Antidiabetic medications

Avoid if

  • You are using it instead of diabetes care
  • You cannot verify the specific formulation

Evidence

Study-level References

gyn-SRC-001Randomized crossover trial
Sourceopen_in_new

Huyen VTT, Phan DV, Thang P, Hoa NKT, Östenson CG. Gynostemma pentaphyllum tea improves insulin sensitivity in type 2 diabetic patients. J Nutr Metab. 2013;2013:765383. doi:10.1155/2013/765383. PMID:23431428.

Population: Drug-naive adults with newly diagnosed type 2 diabetes.

Dose protocol: 6 g daily Gynostemma tea for 4 weeks

Key findings: Improved fasting glucose and insulin sensitivity compared with placebo tea.

Notes: Best direct diabetes trial.

Paper content

This is the most relevant direct human diabetes trial for gynostemma. It suggests improved insulin sensitivity and fasting glucose in drug-naive type 2 diabetes, but the sample was very small and the intervention was a specific tea preparation. That supports cautious adjunctive glucose-control framing, not broad adaptogenic claims.

gyn-SRC-002Randomized controlled trial
Sourceopen_in_new

Martin HJ, Croft KD, Puddey IB, et al. The effect of an orally-dosed Gynostemma pentaphyllum extract (ActivAMP) on body composition in overweight, adult men and women: A double-blind, randomised, placebo-controlled study. Br J Nutr. 2021;126(3):432-442. doi:10.1017/S0007114521002973. PMID:34323337.

Population: Overweight and obese adults.

Dose protocol: 450 mg daily of branded ActivAMP extract for 16 weeks

Key findings: Improved body-fat measures in overweight adults.

Notes: Important but formulation-specific modern RCT.

Paper content

This is the main modern body-composition trial for a branded gynostemma extract. It supports modest fat-mass reduction in overweight adults, but the findings are tied to a specific commercial preparation and should not be generalized to all gynostemma products.

gyn-SRC-003Systematic review
Sourceopen_in_new

Dai N, Zhao FF, Fang M, Pu FL, Kong LY, Liu JP. Gynostemma pentaphyllum for dyslipidemia: A systematic review of randomized controlled trials. Front Pharmacol. 2022;13:917521. doi:10.3389/fphar.2022.917521. PMID:36091752.

Population: Adults with dyslipidemia enrolled in randomized trials of Gynostemma pentaphyllum.

Dose protocol: Various protocols across dyslipidemia RCTs

Key findings: Possible lipid benefit, especially in adjunctive use, but low certainty.

Notes: Supportive only.

Paper content

This review suggests gynostemma may have some lipid effects, especially in adjunctive use, but the certainty is low and many studies carry substantial risk of bias. It supports cautious metabolic framing, not confident dyslipidemia treatment claims.

gyn-SRC-004Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

Lee J, Jin Y, Zhang X, et al. Therapeutic Potential of Gynostemma pentaphyllum Extract for Hair Health Enhancement: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2025;17(5):767. doi:10.3390/nu17050767. PMID:40077637.

Population: 100 adults aged 19 to 60 years with hair health concerns.

Dose protocol: 340 mL/day gynostemma extract for 24 weeks

Key findings: Threefold increase in hair elasticity and density, fourfold increase in hair diameter versus placebo.

Notes: First placebo-controlled hair health trial. Extends gynostemma evidence beyond metabolic endpoints. Large effect sizes need replication.

Paper content

This well-designed double-blind RCT tested 24 weeks of daily Gynostemma pentaphyllum extract in 100 adults. The treatment group showed substantial improvements in hair elasticity, density, and diameter compared to placebo, with improved subjective satisfaction. No severe adverse events were reported. This is the first placebo-controlled human trial examining gynostemma for a dermatological endpoint, extending the supplement's evidence base beyond metabolic outcomes. The effect sizes are large, but the study needs independent replication.

Guides

Setup

Help